NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alexander's, Inc. (NYSE:ALX), Atrion Corporation (NASDAQ:ATRI), FS Bancorp, Inc. (NASDAQ:FSBW), Gilead Sciences, Inc. (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), and Johnson & Johnson (NYSE:JNJ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ALX DOWNLOAD: http://Fundamental-Markets.com/register/?so=ALX
ATRI DOWNLOAD: http://Fundamental-Markets.com/register/?so=ATRI
FSBW DOWNLOAD: http://Fundamental-Markets.com/register/?so=FSBW
GILD DOWNLOAD: http://Fundamental-Markets.com/register/?so=GILD
ABT DOWNLOAD: http://Fundamental-Markets.com/register/?so=ABT
JNJ DOWNLOAD: http://Fundamental-Markets.com/register/?so=JNJ

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Alexander's, Inc. (NYSE:ALX), Atrion Corporation (NASDAQ:ATRI), FS Bancorp, Inc. (NASDAQ:FSBW), Gilead Sciences, Inc. (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), and Johnson & Johnson (NYSE:JNJ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 30th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ALEXANDER'S, INC. (ALX) REPORT OVERVIEW

Alexander's' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Alexander's reported revenue of $58.09MM vs $57.12MM (up 1.71%) and basic earnings per share $3.97 vs $4.11 (down 3.41%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Alexander's reported revenue of $226.94MM vs $207.92MM (up 9.15%) and basic earnings per share $16.91 vs $15.04 (up 12.43%). Alexander's is expected to report earnings on February 12th, 2018. The report will be for the fiscal period ending December 31st, 2017.

To read the full Alexander's, Inc. (ALX) report, download it here: http://Fundamental-Markets.com/register/?so=ALX

-----------------------------------------

ATRION CORPORATION (ATRI) REPORT OVERVIEW

Atrion's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Atrion reported revenue of $37.90MM vs $37.84MM (up 0.18%) and basic earnings per share $4.30 vs $4.17 (up 3.12%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Atrion reported revenue of $143.49MM vs $145.73MM (down 1.54%) and basic earnings per share $15.12 vs $15.67 (down 3.51%). Atrion is expected to report earnings on February 22nd, 2018. The report will be for the fiscal period ending December 31st, 2017.

To read the full Atrion Corporation (ATRI) report, download it here: http://Fundamental-Markets.com/register/?so=ATRI

-----------------------------------------

FS BANCORP, INC. (FSBW) REPORT OVERVIEW

FS's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, FS reported interest income of $12.35MM vs $9.78MM (up 26.31%) and basic earnings per share $1.13 vs $1.21 (down 6.61%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, FS reported interest income of $38.02MM vs $31.71MM (up 19.91%) and basic earnings per share $3.63 vs $2.98 (up 21.81%). FS is expected to report earnings on April 25th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.85. The estimated EPS forecast for the next fiscal year is $5.18 and is expected to report on January 24th, 2019.

To read the full FS Bancorp, Inc. (FSBW) report, download it here: http://Fundamental-Markets.com/register/?so=FSBW

-----------------------------------------

GILEAD SCIENCES, INC. (GILD) REPORT OVERVIEW

Gilead Sciences' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Gilead Sciences reported revenue of $6,512.00MM vs $7,500.00MM (down 13.17%) and basic earnings per share $2.08 vs $2.52 (down 17.46%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Gilead Sciences reported revenue of $30,390.00MM vs $32,639.00MM (down 6.89%) and basic earnings per share $10.08 vs $12.37 (down 18.51%). Gilead Sciences is expected to report earnings on February 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $2.64. The estimated EPS forecast for the next fiscal year is $6.47 and is expected to report on February 6th, 2018.

To read the full Gilead Sciences, Inc. (GILD) report, download it here: http://Fundamental-Markets.com/register/?so=GILD

-----------------------------------------

ABBOTT LABORATORIES (ABT) REPORT OVERVIEW

Abbott Laboratories' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Abbott Laboratories reported revenue of $6,829.00MM vs $5,302.00MM (up 28.80%) and basic earnings per share $0.34 vs -$0.22. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Abbott Laboratories reported revenue of $20,853.00MM vs $20,405.00MM (up 2.20%) and basic earnings per share $0.94 vs $2.94 (down 68.03%). Abbott Laboratories is expected to report earnings on April 18th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.48. The estimated EPS forecast for the next fiscal year is $3.21 and is expected to report on January 23rd, 2019.

To read the full Abbott Laboratories (ABT) report, download it here: http://Fundamental-Markets.com/register/?so=ABT

-----------------------------------------

JOHNSON & JOHNSON (JNJ) REPORT OVERVIEW

Johnson & Johnson's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Johnson & Johnson reported revenue of $19,650.00MM vs $17,820.00MM (up 10.27%) and basic earnings per share $1.40 vs $1.56 (down 10.26%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Johnson & Johnson reported revenue of $71,890.00MM vs $70,074.00MM (up 2.59%) and basic earnings per share $6.04 vs $5.56 (up 8.63%). Johnson & Johnson is expected to report earnings on April 17th, 2018. The report will be for the fiscal period ending March 31st, 2018. According to Zacks Investment Research, based on 11 analysts' forecasts, the consensus EPS forecast for the quarter is $1.72. The reported EPS for the same quarter last year was $1.83. The estimated EPS forecast for the next fiscal year is $8.61 and is expected to report on January 22nd, 2019.

To read the full Johnson & Johnson (JNJ) report, download it here: http://Fundamental-Markets.com/register/?so=JNJ

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.